Ontario fast-tracks life-changing brain cancer drug, becoming first province to publicly fund VORANIGO

COLLEEN GREEN The Standard

Ontario has become the first province in Canada to publicly fund the drug vorasidenib tablets (VORANIGO) for eligible adults living with a specific type of glioma, marking a significant shift in how quickly patients can access breakthrough treatments.

The funding comes through Ontario’s Funding Accelerated for Specific Treatments (FAST) program, an initiative designed to shorten the gap between federal approval, by Health Canada, and public access for patients facing serious, life-altering conditions.

For people diagnosed with glioma, a form of brain cancer, timing can be everything.

Glioma is a type of tumour which begins in the glial cells of the brain, which support and protect nerve cells. There are several forms, ranging from slower-growing tumours to highly aggressive cancers.

Even in cases where gliomas grow more slowly, they can profoundly affect essential functions such as speech, movement, memory, and personality, depending on where in the brain they develop.

Due to the fact the brain controls nearly every aspect of the body, even small changes can have major consequences.

Timing is critical because brain tumours do not wait. As gliomas grow, they can infiltrate surrounding brain tissue, making treatment more complex over time. Early intervention can help delay progression, preserve neurological function, and improve quality of life.

Reducing delays between drug approval and public coverage is so important.

Under traditional pathways, months, or even years, can pass between a drug receiving regulatory approval and being funded through provincial health systems. Patients may face difficult choices: pay out of pocket, seek private insurance coverage, travel for treatment, or go without.

For families already coping with a cancer diagnosis, those delays can be devastating.

In practical terms, delays in public reimbursement can mean: tumours progressing while patients wait, increased anxiety and uncertainty for families, financial strain from attempting to access treatment privately and missed windows where therapies are most effective.

For patients with time-sensitive cancers, like glioma, these gaps are not just administrative, they can alter the course of the disease. For Dr. Aisha Husain, a family physician diagnosed with glioma, the experience underscores how unpredictable, and urgent, brain cancer can be.

What began as years of worsening fatigue and reduced stamina eventually led to an MRI and a life-changing diagnosis.

“I left the specialist’s office feeling stunned,” she recalled. “The first person I called was my husband.”

Like many patients, her journey quickly became a series of waits, waiting for specialist appointments, waiting for surgery, and waiting through the uncertainty of what would come next.

Even after surgery, complications added new challenges. Dr. Husain temporarily lost her ability to speak and experienced paralysis on one side of her body.

“I wanted to speak, and nothing was coming out,” she said.

Recovery required intensive rehabilitation, including speech therapy, physiotherapy, and occupational therapy. Over time, she regained her abilities, describing the brain’s recovery as “miraculous.”

Now, several years into her journey, she lives with the understanding her condition requires ongoing monitoring, and potentially targeted treatment in the future.

For patients like Dr. Husain, faster access to new therapies offers more than medical benefit, it brings peace of mind.

Knowing a treatment is available when needed can reduce the emotional burden which often accompanies a cancer diagnosis.

Accelerated funding pathways like FAST can: provide earlier access to innovative, targeted therapies, help stabilize disease before it worsens, reduce the stress of navigating private payment options and allow patients to focus on recovery and quality of life.

Dr. Husain emphasizes, a diagnosis like glioma reshapes not just health, but the entire care journey, from how families cope to how patients plan for the future.

“It’s about hope,” she said. “Even with a life-altering diagnosis, there is a way forward.”

Ontario’s decision to fund VORANIGO, through an accelerated pathway, reflects a growing recognition speed matters in cancer care, especially for diseases where delays can have lasting consequences.

For patients and families facing glioma and other aggressive cancers, the move signals a shift toward more responsive, patient-centred care.

For many, it may mean the difference between waiting, and having a fighting chance.